We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

95 hedge funds and large institutions have $107M invested in Aralez Pharmaceuticals Inc. in 2016 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

262% more call options, than puts

Call options by funds: $1.34M | Put options by funds: $371K

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

19% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 26

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

6% more funds holding

Funds holding: 90 → 95 (+5)

1% less capital invested

Capital invested by funds: $108M → $107M (-$582K)

Holders
95
Holders Change
+5
Holders Change %
+5.56%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
31
Increased
26
Reduced
22
Closed
26
Calls
$1.34M
Puts
$371K
Net Calls
+$972K
Net Calls Change
+$1.43M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$10.1M
2
PCM
PAR Capital Management
Massachusetts
+$3.91M
3
JAM
JW Asset Management
Florida
+$3.4M
4
HVC
Healthcare Value Capital
New Jersey
+$1.79M
5
KCM
Kingstown Capital Management
New York
+$1.54M

Top Sellers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
-$4.88M
2
State Street
State Street
Massachusetts
-$2.81M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.26M
4
Northern Trust
Northern Trust
Illinois
-$1.83M
5
BIT
BlackRock Institutional Trust
California
-$1.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
FSA
26
Franklin Street Advisors
North Carolina
$558K +$413K +109,491 +184%
LCM
27
Laurion Capital Management
New York
$505K +$577K +152,900 New
PP
28
Paloma Partners
Connecticut
$475K +$543K +143,901 New
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$467K -$883K -233,866 -62%
Goldman Sachs
30
Goldman Sachs
New York
$402K +$343K +90,831 +295%
CS
31
Credit Suisse
Switzerland
$393K +$450K +119,113 New
PP
32
Prospector Partners
Connecticut
$373K – – –
TCIM
33
TIAA CREF Investment Management
New York
$363K -$653K -172,911 -61%
IP
34
Isthmus Partners
Wisconsin
$361K +$234K +62,053 +131%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$349K +$36.5K +9,667 +10%
TAM
36
Tocqueville Asset Management
New York
$333K – – –
GCP
37
GSA Capital Partners
United Kingdom
$305K +$125K +33,100 +56%
AA
38
ALPS Advisors
Colorado
$297K +$67.6K +17,920 +25%
Westfield Capital Management
39
Westfield Capital Management
Massachusetts
$294K – – –
Bank of New York Mellon
40
Bank of New York Mellon
New York
$274K -$425K -112,592 -58%
CHAM
41
Clear Harbor Asset Management
Connecticut
$261K +$298K +79,094 New
O
42
OrbiMed
New York
$225K +$257K +68,143 New
LCS
43
Levin Capital Strategies
New York
$221K +$253K +66,991 New
IAM
44
Integre Asset Management
New York
$208K -$71.5K -18,954 -23%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$207K -$253K -66,980 -52%
Northern Trust
46
Northern Trust
Illinois
$199K -$1.83M -485,604 -89%
GI
47
Greenwood Investments
Massachusetts
$187K +$214K +56,731 New
BCM
48
Bridgeway Capital Management
Texas
$184K -$142K -37,514 -40%
FMA
49
FNY Managed Accounts
New York
$172K +$83K +22,000 +73%
Squarepoint
50
Squarepoint
New York
$155K +$178K +47,100 New
1
2
3 4 5

ARLZ Hedge Fund Activity: Q2 2016 in Review

95 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q2 2016, worth a combined $107M — down 0.54% from $108M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ARLZ positions and 26 closed out — a net gain of 5 holders — while 26 added to existing stakes and 22 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $10.1M. The largest seller was BlackRock Fund Advisors, exiting entirely with an estimated $4.88M sold.

  • 95 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q2 2016, up from 90 in Q1 2016.
  • Funds reported $107M of Aralez Pharmaceuticals Inc. stock for Q2 2016, down 0.54% quarter-over-quarter.
  • 31 funds opened new Aralez Pharmaceuticals Inc. positions in Q2 2016 and 26 closed out, a net change of +5 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q2 2016 was Armistice Capital, an estimated $10.1M added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $4.88M sold.

Based on aggregated 13F filings for Q2 2016.